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ABSTRACT 
This paper estimates medical resource use, direct costs, and productivity losses and costs 
(indirect costs) during episodes of acute otitis media (AOM) in young children. A 24-item 
Internet questionnaire was developed for parents in Belgium (Flanders), France, Germany, 
Italy, The Netherlands, Spain, and the United Kingdom (UK) to report health care resource 
use and productivity losses during the most recent episode of AOM in their child, younger 
than 5 years. The percentage who did not seek medical help for AOM was considerable in 
The Netherlands (28.3%) and the UK (19.7%). Antibiotic use was high, ranging from 60.8% 
(Germany) to 87.1% (Italy). Total costs per AOM episode ranged from €332.00 (The 
Netherlands) to €752.49 (UK). Losses in productivity accounted for 61% (France) to 83% 
(Germany) of the total costs. AOM poses a significant medical and economic burden to 
society.  
 
Keywords: acute otitis media, direct costs, indirect costs 
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1. INTRODUCTION 
Otitis media is one of the most common diseases in early infancy and childhood. A diagnosis 
of acute otitis media (AOM) requires a history of acute onset of signs and symptoms of 
middle-ear inflammation.[1, 2] Otitis media with effusion (OME) is defined as the presence of 
fluid in the middle ear without signs or symptoms of acute ear infection; OME frequently 
follows AOM.[2, 3] AOM does not usually lead to any measurable long-term consequences. 
In about 90% of cases in children older than 2 years, the worst symptoms subside within 
3 days (range 27 days)[2, 4]; in about 40% to 60% of cases in children younger than 2 years, 
the worst symptoms subside within 3 days.[5] However, long-term consequences of AOM can 
occur; OME is the most common cause of acquired hearing loss in childhood. OME also has 
been associated with delayed language development and behavioral problems.[6] 
The incidence of AOM peaks between the ages of 6 and 11 months.[2] In Europe, Germany 
and The Netherlands have reported a cumulative prevalence of 35% by the age of 2 years,[7] 
based on prospective birth cohorts. By the age of 3 years, 50% to 85% of children will have 
had at least one episode of AOM.[2] In Spain, 60% of 4-year-olds will have had AOM, based 
on a retrospective cohort study among pediatricians.[8] Recurrent AOM (≥ 4 episodes per 
year) is common, affecting up to 20% of children younger than 1 year; up to 40% of older 
children eventually have six or more episodes in total.[2]  
Although guidelines on the treatment of AOM differ between countries, the current consensus 
is that in most patients aged 2 years and older, symptomatic treatment (e.g., analgesics) is 
sufficient,[9, 10] and the use of antibiotics should be restricted to help minimise antibiotic 
resistance. However, some guidelines (i.e., in the United Kingdom [UK], the United States 
[US], and France[11]) recommend antibiotics for all children younger than 2 years, and others 
(i.e., in The Netherlands and Scotland)[9] recommend the use of antibiotics only in the case of 
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severe symptoms, persistent signs of disease, or related comorbidity. The French guidelines 
recommend antibiotics for those older than 2 years only in the case of severe symptoms; 
abstention from antibiotics at the initial visit should be followed by a reassessment at 48 to 72 
hours.[11] Regional and national guidelines in Italy[12, 13] recommend giving antibiotics 
only if the symptoms are the same or worse after 48 to 72 hours for all children, except for 
those presenting with severe (otorrhea) or recurrent symptoms, or those with other conditions 
or underlying conditions requiring antibiotic use. There also are differences between countries 
with respect to surgery. In The Netherlands, a restrictive policy regarding antibiotic 
prescriptions is accompanied by high rates of myringotomy procedure.[10]  
Differences in AOM management among different countries might be explained by 
differences in physicians’ and patients’ perceptions and expectations regarding the outcome of 
a physician visit or differences in the organisation of the health care system.[10] Differences 
in the health care system also affect the proportion of parents seeking medical care for their 
child with AOM symptoms. For example, in The Netherlands, patients have to see their 
general practitioner (GP) before accessing other physicians, and there is a strong culture of 
“watchful waiting.” Thus, experts have estimated that only one-third of all cases of AOM 
would result in a GP visit in The Netherlands.[14]  
For most countries, data are lacking on the use of medical resources for AOM, including the 
proportion of cases not seeking medical care. In addition, data are not available to estimate the 
impact of AOM on other direct and indirect costs. It is highly likely that parents of children 
with AOM, both those who do and those who do not seek medical care, will take time off 
work to care for their child and/or buy over-the-counter (OTC) analgesics or topical agents, 
such as ear drops, to ease the symptoms.  
As AOM is one of the most common childhood diseases, the total societal impact of the 
disease can be substantial, and indirect costs associated with losses in productivity at work 
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and at home are likely to constitute a large part of the total costs involved. For example, 
indirect costs have been reported to represent 40% to 60% of the total costs of AOM, 
depending on country, age, and number of previous episodes (Niemela et al., 1999 
[Finland][15]; Capra et al., 2000 [US][16]). The magnitude of the indirect costs will depend 
on the social services and socioeconomic situation in a country, such as the employment rate, 
proportion of part-time workers among women and men, and parental leave arrangements. For 
example, the proportion of part-time employees among employed women aged 20 to 49 years 
with children younger than 12 years ranges from 20% in Spain to 80% in The 
Netherlands.[17] 
Given the differences in health care systems and social services among countries, there is a 
need for country-specific data on direct and indirect costs. Our aim is to describe the use of 
medical resources and the total societal impact of AOM in seven European countries to help 
fill these gaps in the knowledge base.  
2. METHODS 
2.1. Questionnaire and Study Population 
We developed a 24-item questionnaire retrospectively asking parents about health care use 
and productivity losses related to the most recent episode experienced of any disease, 
including AOM, by their children younger than 5 years. The domains covered by the 
questionnaire included characteristics of the disease episode (symptoms, duration, frequency), 
the use of medical resources (number of physician and emergency room [ER] visits, telephone 
consultations, hospitalisations, prescription and OTC drug use including zero use; diagnostic 
tests and surgical interventions were not included), productivity loss by the caregivers (work 
days lost, loss of productivity at work, loss of leisure time), and travel costs. The 
questionnaire was sent electronically to a sample of parents with children younger than 5 
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years from Belgium (Flanders), France, Germany, Italy, The Netherlands, Spain, and the UK, 
who participated in an Internet access panel of Survey Sampling International (SSI), a market 
research agency in Rotterdam, The Netherlands. The panel, which consists of people who 
have elected to participate in surveys sent out by SSI on behalf of its clients, is a general 
consumer panel, not specifically set up for health-related subjects.  
Parents were asked to provide details about the most recent (maximum of 12 months ago) 
illness episode of any type experienced by their child (younger than 5 years). When parents 
had more than one child younger than 5 years, they were asked to complete the questionnaire 
for the child who had most recently been ill. The questionnaire was generic; parents could list 
all kinds of symptoms and diseases. All data, including the diagnosis given by the physician, 
were self-reported by the parents.  
As a pilot study, the questionnaire was first administered to an Internet access panel in 
Belgium (Flanders) and The Netherlands in January 2007. Following the pilot study, we 
developed and included additional questions on the number of health care visits and the 
number of work hours lost. This adapted version of the questionnaire was distributed to access 
panel members in France, Germany, Italy, Spain, and the UK in late April 2007. The Internet 
survey was targeted to parents of young children, and given the likely age of these parents, it 
was expected that they would be a very Internet-literate age group in most Western countries. 
The response rate in the different countries ranged from 17% (UK) to 53% (Belgium 
[Flanders]). The respondents were representative of the countries as a whole with respect to 
geographic background, education, and income, although respondents had higher education 
and income rates than nonrespondents in France, Italy, and Spain.  
2.2. Case Definition and Medical and Other Direct Resource Use 
The questionnaire provided a symptom list, including, among others, earache, running ear, 
cold, fever, and diarrhea, and parents were asked to fill out the symptoms of their child’s most 
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recent illness. In addition, parents were asked to indicate whether they had received a 
diagnosis by a physician and, if so, to provide the diagnosis. Thus, parents provided all 
information on the diagnosis. In the subset of the survey respondents who indicated that the 
most recent illness included AOM symptoms, we identified the following AOM categories: 
Category 1: Physician-Confirmed AOM  
 Parents reported symptoms of earache or running ear and reported a physician visit 
with a diagnosis of otitis, AOM, ear infection, running ear, or "tubes" indicative of 
AOM.  
 Parents reported no symptoms of earache or running ear, but did report a physician 
visit with a diagnosis indicative of AOM. 
Category 2: Symptoms of AOM/Other Diagnosis at Physician Visit  
 Parents reported symptoms of earache or running ear and a physician visit, but did not 
report a medical diagnosis indicative of AOM (e.g., earache may be due to tonsillitis). 
Category 3: Symptoms of AOM/No Physician Visit  
 Parents reported symptoms of earache or running ear, but did not report a physician 
visit. 
Results for category 1 are presented in tables and text. For countries with a high proportion of 
parents not visiting a physician, results for category 3 are highlighted in the text because only 
two countries (UK and The Netherlands) had relatively large numbers in this category. In 
addition, parents were asked how many episodes with the same symptoms their child 
experienced in the past year. 
Parents were asked to report all the health care services used to treat the episode of AOM, 
including physician visits, ER visits, hospitalisations, prescription drugs, and out-of-pocket 
payments for OTC drugs (diagnostic tests and surgical interventions were not included). In 
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addition, they were asked to report direct nonmedical resource use, including travel time, 
parking, and transportation for physician or pharmacy visits.  
2.3. Indirect Resource Use (Productivity Losses)  
Productivity losses included hours of absence from a paid or unpaid job, as well as loss of 
productivity at work and loss of hours of leisure time. Absence from an unpaid job was 
defined as not being able to (1) provide usual informal care to others; (2) carry out any other 
voluntary work; or (3) carry out activities around the house.[18] To investigate loss of 
productivity at work, we asked whether the parents felt less productive during work because 
of their child’s illness (e.g., because they could not concentrate properly). If so, parents with a 
paid job were asked to estimate how many extra hours they would have needed to be as 
productive as when their child was not ill. This question has shown to yield conservative 
results for loss of productivity at work.[19] Loss of leisure time was defined as any time 
during free weekdays or weekends that was spent at a physician or pharmacy visit because of 
the child’s illness. The parent who filled out the questionnaire was asked to fill out any 
productivity loss hours for their partner, the child’s grandparents, or other informal caregivers 
as well. For each type of productivity loss hours (absence from work, loss of productivity at 
work, and loss of leisure time), the hours lost are presented for all informal caregivers 
combined (i.e., the total hours missed due to the disease episode). 
The questionnaire was developed by the authors of this paper and programmed by SSI in 
close collaboration with the authors. In developing the questionnaire, both the Productivity 
and Disease Questionnaire (PRODISQ)[20] and the Health and Labour Questionnaire 
(HLQ)[21] were studied, and relevant items on productivity losses were included in the 
survey questionnaire. We did not use PRODISQ or HLQ because these questionnaires were 
developed to measure productivity loss due to health problems in the working adults and 
contain many items not relevant to our study. 
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2.4. Costing 
Costs per episode of physician-confirmed AOM were calculated from a societal perspective 
using data on health care utilisation and productivity losses from the Internet questionnaire. 
Direct medical costs included costs related to physician visits (primary care, including 
telephone consultations, home visits, and outpatient visits), ER visits, hospitalisations, and 
out-of-pocket payments for prescription and OTC drugs (costs for diagnostic tests and 
surgical interventions were not included). Direct nonmedical costs included parent-reported 
travel costs (based on kilometres driven) and parent-reported parking costs, public 
transportation, and taxi fares for physician or pharmacy visits. For the direct medical costs, we 
used official national sources and published cost-effectiveness studies to obtain unit costs 
(Appendix A). Costs for OTC drugs were derived directly from the questionnaire, where we 
asked the respondents to estimate how much they spent on OTC drugs. In the case of 
prescription drugs, out-of-pocket costs were included only as obtained from the survey 
respondents. The information from the questionnaire on drug use was not detailed enough to 
estimate costs covered by the public payer. Costs for hospital admissions for all the countries 
included in the survey were based on diagnosis-related groups or cost per day for 
hospitalisations for upper respiratory tract disorder and AOM or minor ear procedures. All 
direct medical costs were calculated in 2007 Euros. For indirect costs associated with absence 
from a paid job, average hourly labor costs for the year 2006 were derived from national labor 
statistics. Hourly labor costs of an unpaid job or leisure time were based on net tariffs for 
informal care, such as housekeeping, and either derived from national statistics or estimated to 
be equal to the hourly minimum wage. UK cost prices in pounds were converted to Euros, 
using an exchange rate of £1 = €1.48 (June 12, 2007). We also asked whether any of the lost 
hours had been made up by the parent or a colleague during or after the disease period (except 
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for The Netherlands and Belgium [Flanders]). This has not been netted out in the cost 
calculation, but results are presented in the text.  
Direct medical costs per episode were estimated by multiplying the unit costs by the mean 
units of medical resources used per episode (e.g., mean number of GP visits per episode) and 
weighted by the proportion of episodes for which this type of health care was used. In the 
same way, indirect costs were estimated using results for mean hours of productivity loss or 
leisure time loss, and the proportion of respondents reporting each type of productivity loss.  
The costing was performed in accordance with the Dutch guidelines for pharmacoeconomic 
studies.[22] 
2.5. Statistical Analyses 
Descriptive statistics (proportions, means, medians, standard deviations [SDs]) were 
generated for resources and costs. Mean values were used to estimate the costs for an episode 
of AOM because this allows policymakers to estimate the total costs of treatment for a 
population. 
3. RESULTS 
3.1. Study Population 
Table 1 provides information on the characteristics of the most recent disease episodes in 
children younger than 5 years surveyed in the seven countries. The total numbers of 
completed questionnaires included in the analyses were 1,208 for Belgium (Flanders), 2,059 
for Germany, 2,216 for Spain, 2,071 for France, 2,145 for Italy, 2,425 for The Netherlands, 
and 2,015 for the UK. The ages of the children in the total sample (all kinds of disease 
episodes) ranged from 0 to 4 years, with an even distribution of the sample across 1-year age 
groups. The time elapsed between the disease episode and filling out the questionnaire was 
similar for the different countries, with 64.8% (Italy) to 74.7% (Belgium [Flanders]) of the 
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disease episodes occurring during the previous month, and 9.4% (France) to 16.0% (The 
Netherlands) of the episodes occurring more than 3 months before the questionnaire.  
Out of all the most recent disease episodes, between 13.9% (Spain) and 20.7% (Belgium 
[Flanders]) reported symptoms of AOM, and between 35.8% (UK) and 74.8% (France) of 
these cases had physician-confirmed AOM. In Germany, Italy, Spain, and the UK, about half 
of physician-confirmed AOM episodes were in children younger than 3 years; this proportion 
was higher in Belgium (Flanders) (62%), France (63%), and The Netherlands (70%). The 
mean duration of a physician-confirmed AOM disease episode ranged from 6.7 (SD 4.8) days 
(Italy) to 10.9 (SD 15.9) days (The Netherlands) (Table 1). The mean duration of symptoms 
of AOM for which no medical help was sought was 4.8 (SD 3.0) days in the UK and 4.9 
(SD 3.3) days in The Netherlands; there were very few (< 20) cases of AOM not seeking care 
in the other countries. Parents reported that children who had physician-confirmed AOM 
experienced a mean number of between 2.2 (Germany) and 2.7 (Spain, France, Italy) episodes 
of AOM in the previous year (including the most recent episode). Between 14.2% (Germany) 
and 23.4% (France) of the cases with physician-confirmed AOM experienced four or more 
episodes in the previous year (Table 1), a definition consistent with recurrent AOM. 
3.2. Health Care Use 
The proportion of parents consulting a physician when their child was ill (all illnesses 
combined) varied widely among countries, ranging from 47.0% (The Netherlands) to 88.7% 
(Spain) (Table 1). A physician was more likely to be consulted in cases with symptoms of 
AOM (71.7%98.5%). Although The Netherlands (53.0%) and the UK (42.3%) were the 
countries with the highest proportion of cases of all illnesses that did not seek medical care, 
only 28.3% and 19.7%, respectively, of cases with symptoms of AOM did not consult a 
physician (Table 1).  
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The use of medical resources reflected the organisation of health services in the respective 
countries, with a strong role of the pediatrician in Germany, Spain, and Italy, as opposed to 
the dominant role of the GP in Belgium (Flanders), France, The Netherlands, and the UK. ER 
visits were high in Spain, which is a known feature of the Spanish health care system.[23] GP 
visits at home were most common in Belgium (Flanders), and telephone consultations with a 
physician were more frequent in Italy, The Netherlands, and the UK (Table 2).  
Parents were asked whether their child was admitted to the hospital during the disease 
episode. Percentages were low for episodes of physician-confirmed AOM, ranging from 3.6% 
(Belgium [Flanders]) to 7.7% (Spain).  
Antibiotics were prescribed for the majority of children with physician-confirmed AOM, 
ranging from 60.8% (Germany) to 87.1% (Italy) (Table 2). Data were not available for 
Belgium (Flanders) and The Netherlands because no question on prescription drugs was 
included in the pilot phase of the questionnaire. From the literature we could estimate an 
antibiotics prescription rate of 58% for The Netherlands[24] in children younger than 4 years, 
and for Belgium (Flanders) 85% antibiotic use in children with AOM has been reported.[25] 
The latter might be an overestimation as overall outpatient antibiotics use has declined by 
36% in Belgium over the past decade.[26] Whether this decline applies to antibiotic treatment 
in young children with AOM is not known. 
Parents were asked whether they bought OTC drugs specifically for this episode of AOM. 
The responses differed greatly between countries, ranging from 20.4% (France) to 75.5% 
(Italy), but in countries where few OTC drugs were bought, parents were better equipped at 
home (Table 2). When OTC drugs were bought, a wide range of expenses were reported 
within each country.  
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3.3. Productivity Loss 
In five of the seven countries, caregiver(s) took time off from a paid job in about 20% of the 
physician-confirmed AOM episodes, although this was lower in The Netherlands (11.8%) and 
the UK (18.4%) (Table 3). For caregivers who took time off from paid employment, the mean 
number of hours missed from their paid jobs per episode of physician-confirmed AOM ranged 
from 17.3 (SD 10.4) (UK) to 35.1 (SD 98.3) (Belgium [Flanders]) (Table 3). When comparing 
productivity losses for episodes of physician-confirmed AOM with episodes with symptoms 
of AOM but no physician visit in The Netherlands and the UK (where there were enough 
episodes to do so), there were no differences in the percentages of episodes for which a 
caregiver had to take time off from a paid job. The amount of time taken off was comparable 
for both types of episodes in The Netherlands but longer for the group with a physician visit 
in the UK (mean 15.5 vs. 9.4 hours). Leave of absence from an unpaid job was generally 
reported less often, but the hours taken off were longer (Table 3). We also asked parents about 
impaired productivity at work, due to lack of sleep or worry about their child’s illness. The 
percentage of episodes of physician-confirmed AOM for which parents reported productivity 
loss at work due to the illness of their child was highly variable, ranging from 23.0% (The 
Netherlands) to 62.4% (the UK) (Table 3), with a mean amount of time lost for those 
reporting a productivity loss ranging from 6.7 hours (France) to 22.7 hours (Spain). Many 
parents (37.6%-67.9%) reported that some free time (mean 2.7-6.7 hours) was spent on a 
physician or pharmacist visit(s) (Table 3). In The Netherlands, there were sizeable differences 
in the percentage of episodes for which parents reported leisure time loss, as well as the mean 
number of hours lost between episodes of physician-confirmed AOM (55.1%; 2.7 hours) and 
episodes with symptoms of AOM without a physician visit (17.6%; 1.0 hours); no such 
differences were seen for the UK. 
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Respondents (except in The Netherlands and Belgium) were asked whether a colleague or 
they themselves made up for any of the lost hours at work. Lost hours in a paid job 
(absenteeism) were made up for in 20% (Italy) to 38% (Germany) of the hours; in an unpaid 
job, in 20% (Italy) to 41% (Germany) of the hours; and lost hours due to productivity loss at 
work (presenteeism) were made up for in 6% (Italy) to 37% (Spain) of the hours lost. 
3.4. Cost Analyses 
Direct medical costs ranged from €62.96 in The Netherlands to €214.91 in Spain and 
comprised mainly hospitalisation costs and visits to the GP or pediatrician. Costs for Belgium 
(Flanders) and The Netherlands were lower than for most other countries because use of 
prescription drugs was not recorded, and parents were not asked for the number of physician 
visits in their version of the survey. The direct costs in France, Germany, Italy, Spain, and the 
UK were mainly due to the costs of hospitalisation and visits to physicians (Table 4).  
Indirect costs associated with productivity losses ranged from €267.05 in The Netherlands to 
€588.92 in Germany. The exact composition of these costs varied per country, but 
productivity loss while at work and absence from a paid job contributed greatly to these costs 
because of the relatively high hourly cost of labor. High indirect costs of an episode of AOM 
in the UK were mainly due to the high percentage of parents reporting productivity loss while 
at work. Indirect costs made up 61% to 83% of the total costs related to an episode of AOM 
(Table 4). For the UK and The Netherlands, the costs of an episode with symptoms of AOM 
without a physician visit were estimated. These costs included productivity losses, car travel, 
and out-of-pocket payments for OTC drugs. These episodes cost on average €353.12 in the 
UK and €192.85 in The Netherlands, which is roughly 47% of the total costs of an episode for 
which a physician is visited in the UK and 58% of those costs in The Netherlands. 
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4. DISCUSSION 
The goal of the study was to estimate the total costs of an episode of AOM as reported by the 
parents of young children from seven European countries. As expected, the use of medical 
resources for physician-confirmed AOM very much reflects the organisation of health 
services in the respective countries. The survey responses revealed a substantial burden of 
AOM in terms of both direct medical costs and indirect costs. In particular, the results of our 
study showed that a physician is consulted for most episodes with symptoms of AOM and the 
frequency of antibiotic use was high for AOM, ranging from 60.8% (Germany) to 87.1% 
(Italy). The percentage of children with physician-confirmed AOM admitted to the hospital 
was low, and ranged from 3.6% (Belgium [Flanders]) to 7.7% (Spain). In most of the 
countries studied, the caregiver took time off from a paid job in about 20% of the physician-
confirmed AOM episodes. In addition to time missed from work, reduced productivity at 
work by the parents was reported for around 40% to 47% of physician-confirmed AOM 
episodes. Loss of leisure time ranged from 37.6% to 67.9% of the episodes. The total costs of 
a physician-confirmed AOM episode varied from €332.00 (The Netherlands) to €752.49 
(UK), with indirect costs representing 61% to 83% of the total episode. Episodes for which no 
medical help was sought generated costs of 54% to 58% of a physician-confirmed AOM 
episode. A strength of this Internet survey is that this study determined the costs related to 
episodes with symptoms of AOM for which medical care was not sought as well, which were 
still considerable. This is an important source of information for countries with a relatively 
high percentage of cases treated at home (e.g., The Netherlands and the UK).  
Methodological issues that might limit the generalisability of the survey results include the 
following: the surveyed population may not be representative of the general population 
because of the need for Web access; AOM diagnoses by physicians were not confirmed using 
the medical record; the population was not representative of the whole population; there was a 
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bias toward children with recurrent episodes; there were differences in employment rates 
across countries. These limitations are discussed in detail below. 
4.1. Representativeness of the Surveyed Population 
The results of this study are based on an Internet panel survey on childhood diseases, which 
has shown adequate response rates (i.e., comparable to more conventional postal 
questionnaires) for most countries. The response rate depends on how well the parents with 
young children could be targeted by the market research agency. This again depends on the 
background data available at the market research agency. When this background is 
incomplete, a larger, less targeted wave of invitations is sent out, which will result in lower 
response rates (e.g., Spain and UK). 
The demographics of the sample showed that the geographical distribution of the respondents 
was representative of the population in all countries. Indicators of socioeconomic status 
(education and income) were fairly representative for Italy and The Netherlands. The Belgium 
(Flanders) and German samples were less educated than the population in general, while the 
French and UK samples were more educated. Median income levels were higher in our 
samples for France and Spain.  
4.2. Accuracy of Self-Reported Data 
All data were self-reported, including the medical diagnoses, which were not validated with 
medical records. However it is common for burden-of-disease studies to use patients as the 
only source of information. Studies have shown that the reliability of patients for this purpose 
is adequate.[27-29]  
The symptoms listed were earache, running ear, cold, fever, and diarrhea. Earache is generally 
due to AOM. When earache is due to tonsillitis or pharyngitis, there is also a dysphagia. 
Running ear in young children is mainly due to an AOM spontaneously perforated, or 
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discharge through a myringotomy tube. The other causes of otorrhea are rarer (otitis externa 
and chronic otitis with or without cholesteatoma). Thus the parents are often able to correctly 
diagnose an ear infection without the help of a physician. Vernacchio and colleagues[30] have 
shown that parents’ reporting of their child’s AOM episode occurring in the previous month 
was accurate (positive predictive value: 85%; negative predictive value: 99%).  
Severens and colleagues[31] studied the precision and accuracy of a retrospective, self-
administered questionnaire on sick leave compared with the employer’s absence records. 
They showed that at least 87% of the self-reported results matched with the employer’s data if 
the recall period was 2 months or less. In our surveys, the vast majority of episodes (at least 
78%, depending on country) occurred in the previous 2 months.  
4.3. Bias Toward Recurrent AOM Episodes 
Parents were asked to report on the most recent disease episode. This could have created a 
bias toward recurrent cases of AOM. Children with multiple AOM episodes are more likely to 
have an AOM episode as their most recent disease episode as compared with children who 
had just one AOM episode that year. Furthermore, parents were not asked to differentiate the 
type of otitis media (i.e., AOM, chronic, OME), although the vast majority of otitis media 
cases are generally AOM. Information on the prevalence of recurrent AOM is scarce in the 
medical literature. It is generally agreed that 10% to 20% of children younger than 1 year will 
have recurrent disease (three episodes within 6 months or four episodes within 1 year) and 
that 40% of children will have more than six episodes in their childhood.[2] In our survey, 
14.2% to 23.4% of the children reported four or more episodes in the previous year. The mean 
number of episodes per year obtained from our survey (2.2 to 2.7) seems to be higher than 
reported elsewhere, but there are little data for comparison. In Finland, an average of 2.1 
episodes per child in the first 2 years of life has been reported in the control group of a 
vaccine study.[32] In Spain, 2.2 episodes were reported in the first 5 years of life.[8] 
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However, these studies report an average number of episodes for the entire child population 
investigated, while we report an average number of episodes in children with episodes of 
AOM. A study in older children (mean 3.5 years old) attending day care centres in Finland 
reported an overall average of 1.5 episodes of AOM per year.[15] However, only 41.7% of 
the 736 children had an episode of AOM; therefore, children with AOM had an average of 3.6 
episodes in a year. A large survey of US parents showed that children younger than 5 years 
who had an AOM episode in the previous year had an average of 2.8 episodes per year.[33] 
These last two figures are closer to ours.  
The proportion of physician-confirmed AOM cases occurring in children younger than 1 year 
was low in our study, ranging from 5% (Italy) to 19% (The Netherlands). This finding was 
striking in view of the fact that we had an equal distribution of the sample among the 1-year 
age groups and that the peak incidence of AOM is between 6 and 11 months.[2] This finding 
might have been caused by our focus on the most recent disease episode. Infants frequently 
experience bouts of diarrhea or fever, and therefore chances are high that one of those 
episodes was the most recent one. In Italy and the UK (where the proportion of children 0 to 6 
months old with AOM was lowest), symptoms of diarrhea were reported at least twice as 
often as symptoms of AOM, which seems to confirm this assumption.  
4.4. Differences in Employment Rates Across Countries 
The mother was the respondent in most cases, ranging from 56% (Italy) to 84% (the UK). 
This could have biased the results on productivity loss toward the mother’s perspective, 
although we explicitly asked the respondent to fill out the data on productivity loss for other 
possible caregivers (e.g., father, grandparents) as well. Work days lost from a paid or unpaid 
job largely depend on the labor-force participation of parents with young children, and in 
large part, on the participation of women. In some countries, the employment rate is low, but 
when women do work, they work full-time; in other countries, employment rates are high, but 
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the large majority of women with children work part-time. Employment rates of women aged 
20 to 49 years with children younger than 12 years range from as low as 50% in Italy and 
Spain to as high as 70% in Belgium (Flanders) and The Netherlands.[17] The proportion of 
part-time employees among this group of women ranges from 20% in Spain to 80% in The 
Netherlands. No such large differences between countries exist for men with children younger 
than 12 years; they have an employment rate of around 90%, and only 5% work part-time. 
The high proportion of part-time work in The Netherlands is likely to explain the low 
percentage (13%) of caregivers who needed to stay home from a paid job. The length of 
parental leave also varies greatly among countries in Europe, and is likely to influence the 
results on productivity losses. If respondents with no job or a part-time job were over-
represented in our sample, productivity losses might have been too low, but this does not 
seem to be the case in our samples. For Belgium (Flanders) (65% mothers) and The 
Netherlands (81% mothers), we asked for employment status of the respondent and the 
number of working hours per week, this being 69% and 26 hours in the former and 84% and 
35 hours in the latter country. For only a relatively small percentage of the physician-
confirmed AOM episodes, caregivers reported some kind of productivity loss (around 20% 
for paid work days loss, around 10% of unpaid job loss); therefore, estimates of the mean 
amount of working time lost show a large spread (Table 3). We also estimated productivity 
losses at work. These productivity losses without absence are potentially important, yet 
almost neglected in economic evaluations of health care.[19] A young child’s illness might 
wake a parent in the middle of the night, leaving the parent tired and leading to productivity 
loss at work. The results of the Internet survey show that a large proportion of the parents 
reported this type of productivity loss. The variation between countries probably relates to the 
employment rates in the different countries, but does not explain the high percentage for the 
UK. Nonetheless, in the Yawn and colleagues’ US survey,[33] 31.4% of parents reported 
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having to take some time off work (0.5-1 day only), but in the Finnish day care study, the 
parental leave of absence reached 1.9 days.[32] Another US study[16] found that 45% of 
parents had to take some time off work, for a mean of 5.9 hours. Our estimations seem to be 
lower for the proportion of caregivers needing to take time off, but higher in the amount of 
time not worked.  
4.5. Comparison of the Estimates with Published Data 
The estimates of direct medical care use from the survey were not always consistent with 
results from other published studies. For example, the survey indicated that a physician was 
consulted in 72% of episodes of AOM in The Netherlands, while the Bos and colleagues 
study[14] indicated that only 30% of AOM episodes resulted in a visit to a GP. The 
percentage of cases visiting an ear, nose, and throat (ENT) specialist in The Netherlands from 
the survey (4.3%) was consistent with the referral rate reported by Plasschaert and 
colleagues.[24] However, the ENT specialist visit rates from the survey in Spain (12.0%) 
were much higher than previously reported (3.5%).[34] The latter were proper referral rates; 
however, the percentages in our survey take into account more severe or recurrent AOM 
cases, for which an ENT specialist had probably already been consulted. The high use of 
antibiotics found in the survey, from 60.8% to 87.1%, is comparable to what has been 
reported for the UK,[35] Italy,[36] and Spain[8, 34] but is of some concern because 
antibiotics provide only marginal benefit and promote antibiotic resistance.[9] For example, a 
study in Italy[13] showed that delayed prescription of antibiotics as recommended in Italian 
guidelines resulted in a significant reduction in the number of children who received 
antibiotics; only 34.9% of those eligible for delayed treatment received antibiotics within 
28 days, without an increase in complications.   
The survey found that indirect costs represented 61% to 83% of the total costs per episode, 
somewhat higher than previous estimates of 40% to 60%,[15, 16] which can probably be at 
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least partly explained by the fact that our indirect costs included a broad interpretation of 
productivity loss (e.g., at work and leisure time). In addition, the human capital approach was 
used to estimate the value of time lost from work rather than the more conservative friction 
cost approach. Furthermore, the direct costs were slightly underestimated as diagnostic tests 
and costs of surgical intervention (if any) were not included in the costing. 
5. CONCLUSIONS 
AOM is one of the most common childhood diseases and as such poses a significant medical 
and economic burden to society. The survey approach used in this study allowed a 
comprehensive estimate of the burden of AOM, including direct medical costs, costs for OTC 
drugs, and indirect costs associated with productivity losses. The results showed that indirect 
costs are generally higher than the direct costs and indicate that estimates of the burden of 
AOM that do not include indirect costs underestimate the cost to society of this disease. The 
findings from this study provide valuable input for economic evaluation of new treatments, as 
they estimated both direct medical costs and productivity losses for AOM in seven European 
countries.  
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Table 1. Characteristics of Most Recent (< 12 Months) Disease Episodes 
 Country 
Characteristic 
Belgium 
(Flanders) France Germany Italy 
The 
Netherlands Spain 
United 
Kingdom 
Response rate (%) 65 36 47 41 44 29 17 
No recent (< 12 months) disease episodes, n 99 181 185 307 375 344 135 
Recent disease episodes, n 1,208 2,071 2,059 2,145 2,425 2,216 2,015 
Episodes with physician visit, n (%)  929 (76.9) 1,785 (86.2) 1,624 (78.9) 1,877 (87.5) 1,140 (47.0) 1,965 (88.7) 1,162 (57.7) 
Episodes with symptoms of AOM, 
n (% of total episodes) 
250 (20.7) 400 (19.3) 374 (18.2) 327 (15.2) 481 (19.8) 308 (13.9) 349 (17.3) 
Physician-confirmed AOM,  
n (% of total episodes with symptoms of AOM) 
140 (56.0) 299 (74.8) 204 (54.5) 155 (47.4) 187 (38.9) 183 (59.4) 125 (35.8) 
Symptoms of AOM—other diagnosis,  
n (% of total episodes with symptoms of AOM) 
91 (36.4) 95 (23.8) 156 (41.7) 157 (48.0) 158 (32.8) 119 (38.6) 155 (44.4) 
Symptoms of AOM—no physician consultation, 
n (% of total episodes with symptoms of AOM) 
19 (7.6) 6 (1.5) 14 (3.7) 15 (4.6) 136 (28.3) 6 (1.9) 69 (19.7) 
Duration (days) of episode of physician-confirmed 
AOM, mean (median) 
6.9 (5.0) 7.5 (5.0) 9.2 (7.0) 6.7 (6.0) 10.9 (7.0) 9.8 (6.0) 8.4 (5.0) 
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 Country 
Characteristic 
Belgium 
(Flanders) France Germany Italy 
The 
Netherlands Spain 
United 
Kingdom 
Number of episodes of physician-confirmed AOM 
per child per year, mean  
NA 2.7 2.2 2.7 NA 2.7 2.4 
Children with physician-confirmed AOM with ≥ 4 
episodes in previous year, % 
NA 23.4 14.2 21.9 NA 22.4 14.4 
AOM = acute otitis media; NA = not available because not asked in pilot study. 
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Table 2. Use of Medical Resources for Episodes of Physician-Confirmed Otitis Media 
 Country 
Medical Resource 
Belgium 
(Flanders) 
(n = 140) 
France 
(n = 299) 
Germany 
(n = 204) 
Italy 
(n = 155) 
The 
Netherlands 
(n = 187) 
Spain 
(n = 183) 
United 
Kingdom 
(n = 125) 
Physician consulted, %        
General practitioner practice 60.7 71.6 17.2 3.2 87.2 8.7 82.4 
General practitioner home visit 17.1 5.0 2.0 9.0 1.1 1.6 1.6 
Pediatrician 26.4 25.1 79.9 87.7 3.7 90.2 19.2 
Emergency room 2.1 4.3 10.3 15.5 2.1 27.9 10.4 
Ear, nose, and throat 1.4 10.7 28.9 19.4 4.3 12.0 4.8 
Other 0.7 7.4 0.5 1.9 4.3 4.4 8.0 
Telephone consult 2.1 1.7 0.5 12.3 7.0 1.1 8.8 
Hospitalisation, % 3.6 6.7 4.4 3.9 4.3 7.7 4.0 
Duration, days        
Mean (SD)  3.6 (5.8) 1.6 (0.9) 2.6 (2.1) 6.8 (2.5) 1.4 (0.5) 2.9 (2.4) 2.8 (2.7) 
Median 1.0 1.0 1.0 6.5 1.0 2.0 1.0 
Antibiotics, %  NA 76.3 60.8 87.1 NA 82.5 84.8 
Other prescribed drugs, % NA 21.7 19.1 9.0 NA 14.8 6.4 
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 Country 
Medical Resource 
Belgium 
(Flanders) 
(n = 140) 
France 
(n = 299) 
Germany 
(n = 204) 
Italy 
(n = 155) 
The 
Netherlands 
(n = 187) 
Spain 
(n = 183) 
United 
Kingdom 
(n = 125) 
Episodes with out-of-pocket payment for 
prescription drugs, % 
NA 17.7 9.3 70.3 NA 82.5 0.8 
Over-the-counter drugs        
Bought for this episode, % 60.7 20.4 32.4 75.5 61.5 63.9 60.0 
Already in house, % 24.3 61.9 44.6 18.7 16.0 29.0 30.4 
NA = not available; SD = standard deviation.  
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Table 3. Productivity Loss and Travel-Related Costs for Episodes With Physician-Confirmed Acute Otitis Media 
Productivity Loss and Travel-
Related Cost 
Belgium 
(Flanders) 
(n = 140) 
France 
(n = 299) 
Germany 
(n = 204) 
Italy 
(n = 155) 
The 
Netherlands 
(n = 187) 
Spain 
(n = 183) 
United 
Kingdom 
(n = 125) 
Caregiver stayed at home from a paid 
job, % 
20.0 23.1 20.1 23.9 11.8 26.2 18.4 
Hours
a
        
Mean (SD) 35.1 (98.3) 21.0 (20.9) 26.1 (47.8) 22.5 (17.1) 28.9 (37.4) 22.5 (30.1) 17.3 (10.4) 
Median 13.0 16.0 10.0 16.0 16.0 12.0 16.0 
Caregiver stayed at home from an 
unpaid job, % 
7.1 10.0 26.5 23.2 5.9 18.6 16.8 
Hours
a
        
Mean (SD) 30.8 (25.5) 14.6 (15.9) 39.2 (70.6) 26.0 (24.3) 59.7 (96.5) 21.4 (23.7) 26.8 (29.9) 
Median 23.0 8.0 18.0.0 20.0 30.0 12.0 15.0 
Parent-reported productivity loss at 
work, % 
40.7 46.5 40.7 43. 9 23.0 47.0 62.4 
Hours
a
        
Mean (SD) 6.9 (10.1) 6.7 (9.5) 19.2 (37.5) 14.8 (19.4) 14.9 (46.5) 22.7 (53.3) 13.7 (15.2) 
Median 4.0 4.0 10.0 7.5 4.0 10.0 8.0 
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Productivity Loss and Travel-
Related Cost 
Belgium 
(Flanders) 
(n = 140) 
France 
(n = 299) 
Germany 
(n = 204) 
Italy 
(n = 155) 
The 
Netherlands 
(n = 187) 
Spain 
(n = 183) 
United 
Kingdom 
(n = 125) 
Parent-reported leisure time loss, % 67.9 41.8 52.5 58.7 55.1 59.6 37.6 
Hours
a
        
Mean (SD) 2.9 (3.9) 3.5 (5.5) 5.8 (10.5) 3.8 (4.3) 2.7 (5.6) 6.7 (16.9) 3.5 (7.4) 
Median 2.0 2.0 2.5 2.5 1.3 2.5 2.0 
Episodes requiring travel by car, % 81.4 67.6 77.0 80.6 76.6 58.5 64.0 
Car kilometres        
Mean (SD) 11.5 (11.8) 13.9 (22.6) 24.2 (40.0) 16.4 (54.0) 11.4 (21.1) 22.3 (41.5) 14.4 (56.8) 
Median  6.0 7.5 12.0 8.0 5.0 10.0 4.0 
SD = standard deviation. 
Percentage of episodes with physician-confirmed acute otitis media for which caregiver(s) stayed home from a paid job or parent(s)-reported productivity loss 
or leisure time loss; 
a
 Applies to the subgroup of episodes for which this type of productivity loss was reported. 
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Table 4. Direct and Indirect Costs per Episode of Physician-Confirmed Otitis Media 
Costs 
Belgium 
(Flanders) 
(n = 140) 
France 
(n = 299) 
Germany 
(n = 204) 
Italy 
(n = 155) 
The Netherlands 
(n = 187) 
Spain 
(n = 183) 
United Kingdom 
(n = 125) 
Direct medical, € 98.99
a
 169.82 107.88 163.94 62.96
a
 214.91 157.35 
Direct nonmedical, € 2.41 6.17 8.76 10.87 1.99 4.68 10.82 
Indirect, € 327.05 270.46 588.92 351.65 267.05 388.37 584.32 
Total, € 428.45 440.45 705.56 526.46 332.00 607.96 752.49 
Indirect/Total 76% 61% 83% 67% 80% 64% 78% 
a 
Prescription drugs and frequency of physician visits are not included (frequency was set to 1 visit). 
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Appendix Table 1a. Distribution of Survey and Reference Data by Region 
Country Region Survey (%) Reference Data (%) 
Belgium (Flemish provinces) Antwerpen 29.2 27.7 
Limburg 12.8 13.9 
Oost Vlaanderen 22.2 22.9 
Vlaams Brabant 16.4 17.1 
West Vlaanderen 19.5 18.5 
Germany (Nielsen regions)
a
 Hamburg, Bremen, Schleswig-Holstein, Niedersachsen 17.7 15.8 
Nordrhein-Westfalen 19.1 21.6 
Hessen, Rheinland-Pfalz, Saarland, Baden-Württemberg 24.3 26.4 
Bayern  15.0 15.0 
Berlin 4.9 4.4 
Brandenburg, Sachsen-Anhalt, Mecklenburg-Vorpommern 8.3 10.7 
Thüringen, Sachsen 10.8 6.1 
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Country Region Survey (%) Reference Data (%) 
Spain (Nielsen regions)
a
 Barcelona 14.3 11.9 
Centro 3.5 12.2 
Este 3.1 6.2 
Levante 7.0 15.6 
Madrid 17.5 13.4 
Nord-oeste 2.5 9.2 
Norte 2.7 7.7 
Sud 49.5 22.8 
France (Nielsen regions)
a
 Parisienne: Ile de France 23.8 19.6 
Nord Est: Picardie, Haute Normandie, Nord Pas de Calais, 
Champagne Ardennes, Lorraine, Alsace 
20.7 20.7 
Grand Ouest: Haute Normandie, Basse Normandie, Bretagne, Centre, 
Pays de Loire, Poitou 
20.6 18.9 
Centre + Est: Centre, Bourgogne, Limousin, Auvergne, Franche 
Comté, Rhône Alpes 
14.2 16.5 
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Country Region Survey (%) Reference Data (%) 
Sud Ouest + Sud Est: Aquitaine, Midi Pyrenees, Rhône Alpes, 
Languedoc Roussillon, Provence Alpes Côte d’Azur/ Corse 
20.6 24.3 
Italy (ISTAT regions)
b
 Nord Occidentale 34.7 26.8 
Nord Orientale 18.5 18.6 
Centrale 23.2 19.3 
Meridionale 15.6 23.9 
Insulare 8.1 11.4 
The Netherlands (Nielsen regions)
a
 Amsterdam, Den Haag, Rotterdam 10.1 15.2 
Noord-Holland, Zuid-Holland, Utrecht 32.5 29.1 
Friesland, Groningen, Drenthe 12.5 10.5 
Overijssel, Gelderland, Flevoland 22.3 20.9 
Zeeland, Brabant, Limburg 22.7 24.3 
UK (Combination of Nielsen regions)
c
 South England 14.2 13.3 
London 18.1 20.4 
Central England 23.6 22.4 
Yorkshire 11.2 10.2 
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Country Region Survey (%) Reference Data (%) 
North England 16.0 16.3 
Scotland 8.1 9.2 
Wales  9.0 8.2 
ISTAT = Italian National Statistics Institute; UK = United Kingdom. 
a
 Nielsen regions: regions as defined by AC Nielsen, a marketing intelligence service. Reference data for the regions were provided by Survey Sampling 
International.  
b
 ISTAT regions: regions as defined by the Italian National Statistics.  
c
 For the UK, 13 Nielsen regions were combined into 7 regions. 
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Appendix Table 1b. Comparison of Educational Level Between Survey and Reference Data 
Country 
Survey (%) Reference Data
a
 (%) 
Low Medium High Low Medium High 
Belgium 6 88 6 31 36 33 
Germany 51 35 14 16 62 22 
Spain 20 37 43 48 21 31 
France 2 44 54 28 43 29 
Italy 9 87 4 46 42 11 
The Netherlands 22 48 31 29 46 24 
UK 7 29 64 37 35 28 
UK = United Kingdom. 
a
 Data for the age group 25 to 44 years of age. 
Sources: Belgium: Levensstandaard—Inkomsten en Bezoldigingen, 2009[1]; Oostenbrink et al., 2004[2]; Germany: Statistisches Bundesamt Deutschland, 
2003[3]; Spain: Instituto Nacional de Estadistica, 2001[4]; France: National Institute of Statistics and Economic Studies, 2003[5]; Italy: ISTAT demographic 
analysis, 2000[6]; The Netherlands: Het Centraal Bureau voor de Statistiek, 2004[7]; UK: Office of National Statistics, 2001[8].  
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Appendix Table 1c. Comparison of Gross Yearly Household Income Between Survey and Reference Data 
Country 
Survey 
(Median €) 
Reference Data
a
 
(Median €) 
Belgium NA  
Germany 23,969 37,178 
Spain 28,586 18,000 
France 31,734 24,065 
Italy 28,611 28,783 
The Netherlands NA  
UK 35,500 30,434 
NA = not available, because data on household income were not asked for in the pilot survey in Belgium and The Netherlands; UK = United Kingdom. 
a
 Data for the age group 25 to 44 years of age. 
Sources: Belgium: Levensstandaard—Inkomsten en Bezoldigingen, 2009[1]; Oostenbrink et al., 2004[2]; Germany: Statistisches Bundesamt Deutschland, 
2003[3]; Spain: Instituto Nacional de Estadistica, 2001[4]; France: National Institute of Statistics and Economic Studies, 2003[5]; Italy: ISTAT demographic 
analysis, 2000[6]; The Netherlands: Het Centraal Bureau voor de Statistiek, 2004[7]; UK: Office of National Statistics, 2001[8]9.  
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Appendix Table 2. Belgium 
Resource 
Cost per Unit 
(Euros) % Users Mean Units/User Cost Per Episode (Euros) 
Direct cost     
Medical      
Pediatrician visit 31.80 26.0 1.00 8.40 
GP visit weekday 20.79 55.0 1.00 11.43 
GP visit night 50.57 1.0 1.00 0.36 
GP visit weekend 31.18 7.0 1.00 2.23 
Home visit 28.00 17.0 1.00 4.80 
Telephone consult 10.40 2.0 1.00 0.22 
Emergency visit 36.38 2.0 1.00 0.78 
Specialist (ENT)/ other visit 31.80 2.0 1.00 0.68 
Hospitalisation/LOS 468.00 4.0 3.60 60.17 
OTC medicines 16.32 61.0  9.91 
Total medical    98.99 
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Resource 
Cost per Unit 
(Euros) % Users Mean Units/User Cost Per Episode (Euros) 
Nonmedical     
Travel 2.96 81.0  2.41 
Total direct cost    101.40 
Indirect cost     
Absence from paid work (hours) 30.55 20.0 35.09 214.38 
Absence from unpaid work (hours) 6.37 7.0 30.75 13.99 
Productivity time lost at work (hours) 30.55 41.0 6.91 86.01 
Leisure time lost (hours) 6.37 68.0 2.93 12.67 
Total Indirect    327.05 
TOTAL COSTS    428.45 
% of costs indirect costs    76.0 
ENT = ear, nose, and throat; GP = general practitioner; LOS = length of stay; OTC = over-the-counter. 
Sources for unit costs: Institut National d’Assurance Maladie-Invalidité, 2007 tariff[9]; Financiële Feedback per Pathologie, 2003 tariff inflated for 2006[10]; 
Levensstandaard—Inkomsten en Bezoldigingen, 2009[1]; Oostenbrink et al., 2004[2]; Nationale Bank van België, 2009[11]; Jaarlijkse Inflatie, 1991-2008[12]. 
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Appendix Table 3. France 
Resource 
Cost per Unit 
(Euros) % Users Mean Units/User Cost Per Episode (Euros) 
Direct cost     
Medical      
Pediatrician visit 23,00 25.0 1.64 9.43 
GP visit 22.00 72.0 1.63 25.82 
Home visit 31.00 5.0 1.33 2.07 
Telephone consult 0.00 2.0 1.40 0.00 
Emergency visit 28.00 4.0 1.31 1.47 
Specialist (ENT) visit 23.00 11.0 1.81 4.58 
Other doctor visit 23.00 7.0 1.36 2.19 
Hospitalisation/LOS 1,080 7.0 1.58 119.45 
Out-of-pocket for prescription 12.67 17.0  2.20 
OTC medicines 12.85 20.0  2.62 
Total medical    169.82 
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Resource 
Cost per Unit 
(Euros) % Users Mean Units/User Cost Per Episode (Euros) 
Nonmedical     
Travel 9.00 69.0  6.17 
Total direct cost    175.99 
Indirect cost     
Absence from paid work (hours) 30.30 23.0 21.04 147.09 
Absence from unpaid work (hours) 10.00 10.0 14.63 14.68 
Productivity time lost at work (hours) 30.30 46.0 6.69 94.24 
Leisure time lost (hours) 10.00 42.0 3.45 14.44 
Total Indirect    270.46 
TOTAL COSTS    440.45 
% of costs indirect costs    60.58% 
ENT = ear, nose, and throat; GP = general practitioner; LOS = length of stay; OTC = over-the-counter. 
Source for unit costs: Sécurité Sociale L’Assurance Maladie, 2009[13]. 
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Appendix Table 4. Germany 
Resource 
Cost per Unit 
(Euros) % Users Mean Units/User Cost Per Episode (Euros) 
Direct cost     
Medical      
Pediatrician visit 19.40 80.0 1.89 29.28 
GP visit 19.40 17.0 2.20 7.32 
Home visit 35.40 2.0 1.00 0.69 
Telephone consult 1.40 0.0 2.00 0.01 
Emergency visit 20.00 16.0 1.09 3.49 
Specialist (ENT) visit 20.40 29.0 2.10 12.40 
Other doctor visit 13.04 0.0 12.00 0.77 
Hospitalisation/LOS 1,205.98 4.0 1.00 48.24 
Out-of-pocket for prescription 28.54 9.0  2.66 
OTC medicines 10.11 30.0  3.02 
Total medical    107.88 
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Resource 
Cost per Unit 
(Euros) % Users Mean Units/User Cost Per Episode (Euros) 
Nonmedical     
Travel 10.64 82.0  8.76 
Total direct cost    116.64 
Indirect cost     
Absence from paid work (hours) 29.05 20.0 26.12 152.51 
Absence from unpaid work (hours) 15.60 26.0 39.20 161.89 
Productivity time lost at work (hours) 29.05 41.0 19.22 227.13 
Leisure time lost (hours) 15.60 52.0 5.79 47.39 
Total Indirect    588.92 
TOTAL COSTS    705.56 
% of costs indirect costs    83.47 
ENT = ear, nose, and throat; GP = general practitioner; LOS = length of stay; OTC = over-the-counter. 
Sources for unit costs: Einheitlicher Bewertungsmaßstab für ärztliche Leistungen, 2009[14]; G-DRG browser version, 2007[15]; German statistical office, 
2001 and 2007[16]. 
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Appendix Table 5. Italy 
Resource Cost per Unit (Euros)  % Users Mean Units/User Cost Per Episode (Euros) 
Direct cost     
Medical      
Pediatrician visit 20.90 88.0 1.58 28.99 
GP visit 15.24 3.0 1.00 0.49 
Home visit 25.82 9.0 1.57 3.66 
Telephone consult 15.24 12.0 1.47 2.75 
Emergency visit 141.00 15.0 1.29 27.28 
Specialist (ENT) visit 20.66 19.0 1.30 5.20 
Other doctor visit 20.66 2.0 2.00 0.80 
Hospitalisation/LOS 263.91 4.0 6.83 69.81 
Out-of-pocket for prescription 14.08 68.0  9.63 
OTC medicines 20.44 75.0  15.33 
Total medical    163.94 
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Resource Cost per Unit (Euros)  % Users Mean Units/User Cost Per Episode (Euros) 
Nonmedical     
Travel 13.59 80.0  10.87 
Total direct cost    174.81 
Indirect cost     
Absence from paid work (hours) 22.70 24.0 22.49 121.85 
Absence from unpaid work (hours) 10.00 23.0 26.00 60.39 
Productivity time lost at work (hours) 22.70 44.0 14.79 147.33 
Leisure time lost (hours) 10.00 59.0 3.76 22.08 
Total Indirect    351.65 
TOTAL COSTS    526.46 
% of costs indirect costs    66.80 
ENT = ear, nose, and throat; GP = general practitioner; LOS = length of stay; OTC = over-the-counter. 
Sources for unit costs: Approvazione Della Tariffa Minima Nazionale Degli Onorari Per Le Prestazioni Medico-Chirurgiche Ed Odontoiatriche, 1992[17]; Thiry 
et al., 2004[18]; Panatto et al., 2009[19]; DRG national tariffs[20]; ISTAT demographic analysis, 2002[21].  
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Appendix Table 6. The Netherlands 
Resource 
Cost per Unit 
(Euros) % Users Mean Units/User Cost Per Episode (Euros) 
Direct cost     
Medical      
Pediatrician visit 81.16 4.0 1.00 3.04 
GP visit weekday 21.02 78.0 1.00 16.30 
GP visit night 21.02 1.0 1.00 0.22 
GP visit weekend 21.02 13.0 1.00 2.70 
Home visit 42.04 1.0 1.00 0.45 
Telephone consult 10.51 7.0 1.00 0.73 
Emergency visit 144.63 2.0 1.00 3.09 
Specialist (ENT)/other visit 81.16 9.0 1.00 6.94 
Hospitalisation/LOS 422.97 4.0 1.38 24.88 
OTC medicines 7.48 61.0  4.60 
Total medical    62.96 
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Resource 
Cost per Unit 
(Euros) % Users Mean Units/User Cost Per Episode (Euros) 
Nonmedical     
Travel 2.55 78.0  1.99 
Total direct cost    63.95 
Indirect cost     
Absence from paid work (hours) 32.21 16.0 21.58 108.03 
Absence from unpaid work (hours) 8.64 6.0 72.62 34.34 
Productivity time lost at work (hours) 32.58 23.0 14.93 111.85 
Leisure time lost (hours) 8.64 55.0 2.70 12.84 
Total Indirect    267.05 
TOTAL COSTS    332.00 
% of costs indirect costs    80.0 
ENT = ear, nose, and throat; GP = general practitioner; LOS = length of stay; OTC = over-the-counter. 
Sources for unit costs: Oostenbrink et al., 2004[2].  
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Appendix Table 7. Spain 
Resource Cost per Unit (Euros) % Users Mean Units/User Cost Per Episode  (Euros) 
Direct cost     
Medical      
Pediatrician visit 33.40 90.16 1.71 51.36 
GP visit 33.40 8.74 2.13 6.21 
Home visit 81.50 1.64 1.00 1.34 
Telephone consult 33.40 1.09 1.00 0.37 
Emergency visit 135.75 27.87 1.20 45.25 
Specialist (ENT) visit 58.54 12.02 1.50 10.56 
Other doctor visit 33.40 4.37 2.14 3.13 
Hospitalisation/LOS 315.53 7.65 2.93 70.69 
Out-of-pocket for prescription 19.68 80.87  15.92 
OTC medicines 15.79 63.93  10.10 
Total medical    214.92 
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Resource Cost per Unit (Euros) % Users Mean Units/User Cost Per Episode  (Euros) 
Nonmedical     
Travel 7.58 61.75  4.68 
Total direct cost     
Indirect cost     
Absence from paid work (hours) 18.60 26.23 22.54 109.97 
Absence from unpaid work (hours) 10.00 18.58 21.35 39.67 
Productivity time lost at work (hours) 18.60 46.99 22.72 198.60 
Leisure time lost (hours) 10.00 59.56 6.74 40.12 
Total indirect    388.37 
TOTAL COSTS    607.96 
% of costs indirect costs    63.88 
ENT = ear, nose, and throat; GP = general practitioner; LOS = length of stay; OTC = over-the-counter. 
Sources for unit costs: Asensi et al., 2004[22]; Navas et al., 2005[23]; Diari Oficial de la Generalitat de Catalunya, 200724]; Indicador laboral de comunidades 
autonomas IESE-ADECCO (ILCA), 2006[26]; Oblikue Database (eSalud)[26] (costs adjusted to 2007). 
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Appendix Table 8. UK 
Resource 
Cost per Unit 
(Euros) % Users Mean Units/User Cost Per Episode (Euros) 
Direct cost     
Medical      
Pediatrician visit 123.40 19.0 1.50 35.17 
GP visit 41.91 82.0 1.44 49.49 
Home visit 67.52 2.0 1.00 1.35 
Telephone consult 25.61 9.0 1.45 3.34 
Emergency visit 67.52 10.0 1.15 7.76 
Specialist (ENT) visit 123.40 5.0 2.17 13.39 
Other doctor visit 123.40 8.0 1.40 13.82 
Hospitalisation (for total stay) 715.92 4.0 1 28.64 
Out-of-pocket for prescription 23.68 1.0  0.19 
OTC medicines 7.00 60.0  4.20 
Total medical    157.35 
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Resource 
Cost per Unit 
(Euros) % Users Mean Units/User Cost Per Episode (Euros) 
Nonmedical     
Travel 15.36 70.0  10.82 
Total direct cost    168.17 
Indirect cost     
Absence from paid work (hours) 46.03 18.0 17.26 146.19 
Absence from unpaid work (hours) 7.92 17.0 26.76 35.61 
Productivity time lost at work (hours) 46.03 62.0 13.65 392.18 
Leisure time lost (hours) 7.92 38.0 3.47 10.34 
Total indirect    584.32 
TOTAL COSTS    752.49 
% of costs indirect costs    77.65 
ENT = ear, nose, and throat; GP = general practitioner; LOS = length of stay; OTC = over-the-counter; UK = United Kingdom. 
Sources for unit costs: Personal Social Services Research Unit, 200827]; National Schedule of Reference Costs, 2005-2006[28]; Office of National Statistics, 
2006[29]; Department for Business, Enterprise and Regulatory Reform, 2007[30]. Exchange rate, July 18, 2009: £1 = €1.16410.
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